WEST

Generate Collection | Print

Search Results - Record(s) 1 through 10 of 13 returned.

☐ 1. Document ID: US 20030044893 A1

L2: Entry 1 of 13 File: PGPB Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044893
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030044893 A1

TITLE: Nectin polypeptides, polynucleotides, methods of making and use thereof

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baum, Peter R.	Seattle	WA	US	
Fanslow, William C. III	Normandy Park	WA	US	
Lofton, Timothy E.	Marysville	WA	US	
Sorensen, Eric A.	Lynnwood	WA	US	
Youakim, Adel	Seattle	WA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/7.1, 514/12, 530/350, 530/388.1, 536/23.53

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 2. Document ID: US 20020168712 A1

L2: Entry 2 of 13 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168712
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020168712 A1

TITLE: Molecules designated LDCAM

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baum, Peter Robert	Seattle	WA	US	
Fanslow, William Christian III	Seattle	WA	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 3. Document ID: US 20020042368 A1

L2: Entry 3 of 13 File: PGPB Apr 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020042368
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020042368 A1

TITLE: Integrin antagonists

PUBLICATION-DATE: April 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fanslow, William C. III	Seattle	WA	US	
Cerretti, Douglas P.	Seattle	WA	US	
Poindexter, Kurt M.	Seattle	WA	US	
Black, Roy A.	Seattle	WA	US	

US-CL-CURRENT: 514/12; 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 4. Document ID: US 20020041864 A1

L2: Entry 4 of 13 File: PGPB Apr 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020041864
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020041864 A1

TITLE: Method for treatment of tumors using photodynamic therapy

PUBLICATION-DATE: April 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fanslow, William C. III	Normandy Park	WA	US	
Thomas, Elaine K.	Seattle	WA	US	

US-CL-CURRENT: 424/85.1; 424/155.1, 604/20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 5. Document ID: US 20020039992 A1

L2: Entry 5 of 13 File: PGPB Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039992
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020039992 A1

TITLE: Tek antagonists

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cerretti, Douglas P.	Seattle	WA	US	
Borges, Luis G.	Seattle	WA	US	
Fanslow, William C. III	Normandy Park	WA	US	

US-CL-CURRENT: 514/2; 424/130.1, 435/184, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 6. Document ID: US 6410711 B1

L2: Entry 6 of 13 File: USPT Jun 25, 2002

US-PAT-NO: 6410711
DOCUMENT-IDENTIFIER: US 6410711 B1
**** See image for Certificate of Correction ****

TITLE: DNA encoding CD40 ligand, a cytokine that binds CD40

DATE-ISSUED: June 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
Fanslow; William C.	Normandy Park	WA		
Spriggs; Melanie K.	Seattle	WA		
Srinivasan; Subhashini	Greenbrae	CA		
Gibson; Marylou G.	Carlsbad	CA		
Morris; Arvia E.	Seattle	WA		
McGrew; Jeffrey T.	Seattle	WA		

US-CL-CURRENT: 536/23.5; 435/252.3, 435/320.1, 435/455, 435/69.1, 435/69.5, 530/350, 530/351, 536/23.1, 536/23.4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 7. Document ID: US 6391637 B1

L2: Entry 7 of 13 File: USPT May 21, 2002

US-PAT-NO: 6391637
DOCUMENT-IDENTIFIER: US 6391637 B1

TITLE: Use of CD40 ligand, a cytokine that binds CD40, to stimulate hybridoma cells

DATE-ISSUED: May 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA	98110	
Fanslow; William C.	Federal Way	WA	98023	
Spriggs; Melanie K.	Seattle	WA	98119	
Srinivasan; Subhashini	Kirkland	WA	98034	
Gibson; Marylou G.	Carlsbad	CA	92009	

US-CL-CURRENT: 435/377; 435/2, 435/326, 435/375, 435/383

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 8. Document ID: US 6290972 B1

L2: Entry 8 of 13 File: USPT Sep 18, 2001

US-PAT-NO: 6290972
DOCUMENT-IDENTIFIER: US 6290972 B1

TITLE: Method of augmenting a vaccine response by administering CD40 ligand

DATE-ISSUED: September 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
Fanslow; William C.	Federal Way	WA		
Spriggs; Melanie K.	Seattle	WA		
Srinivasan; Subhashini	Kirkland	WA		
Gibson; Marylou G.	Carlsbad	CA		

US-CL-CURRENT: 424/278.1; 435/440, 435/69.1, 514/2, 514/8, 514/885, 530/350, 536/23.1, 536/23.4, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 9. Document ID: US 6264951 B1

L2: Entry 9 of 13 File: USPT Jul 24, 2001

US-PAT-NO: 6264951
DOCUMENT-IDENTIFIER: US 6264951 B1

TITLE: Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L

DATE-ISSUED: July 24, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
Fanslow; William C.	Federal Way	WA		
Spriggs; Melanie K.	Seattle	WA		
Srinivasan; Subhashini	Kirkland	WA		
Gibson; Marylou G.	Carlsbad	CA		

US-CL-CURRENT: 424/184.1; 424/185.1, 424/85.1, 514/12, 514/2, 514/8, 514/885, 530/350, 530/351

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 10. Document ID: US 6087329 A

L2: Entry 10 of 13 File: USPT Jul 11, 2000

US-PAT-NO: 6087329
DOCUMENT-IDENTIFIER: US 6087329 A

TITLE: CD40 ligand polypeptide

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
Fanslow; William C.	Federal Way	WA		
Spriggs; Melanie K.	Seattle	WA		

US-CL-CURRENT: 514/8; 514/2, 514/885, 530/350, 530/351

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

Generate Collection Print

Term	Documents
CD40L.USPT,PGPB.	755
CD40LS.USPT,PGPB.	2
CD40.USPT,PGPB.	1969
CD40S	0
LIGAND.USPT,PGPB.	54478
LIGANDS.USPT,PGPB.	44605
(1 AND (CD40L OR (CD40 ADJ LIGAND))).USPT,PGPB.	13
(L1 AND (CD40L OR CD40 ADJ LIGAND)).USPT,PGPB.	13

Display Format: - Change Format

Previous Page Next Page

WEST

Generate Collection | Print

Search Results - Record(s) 11 through 13 of 13 returned.

☐ 11. Document ID: US 5981724 A

L2: Entry 11 of 13 File: USPT Nov 9, 1999

US-PAT-NO: 5981724
DOCUMENT-IDENTIFIER: US 5981724 A

TITLE: DNA encoding CD40 ligand, a cytokine that binds CD40

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
Fanslow; William C.	Federal Way	WA		
Spriggs; Melanie K.	Seattle	WA		
Srinivasan; Subhashini	Kirkland	WA		
Gibson; Marylou G.	Carlsbad	CA		
Morris; Arvia E.	Seattle	WA		
McGrew; Jeffrey T.	Seattle	WA		

US-CL-CURRENT: 536/23.5; 435/252.3, 435/320.1, 435/455, 435/471, 435/69.1, 435/69.7, 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 12. Document ID: US 5962406 A

L2: Entry 12 of 13 File: USPT Oct 5, 1999

US-PAT-NO: 5962406
DOCUMENT-IDENTIFIER: US 5962406 A
**** See image for Certificate of Correction ****

TITLE: Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same

DATE-ISSUED: October 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
Fanslow; William C.	Federal Way	WA		
Spriggs; Melanie K.	Seattle	WA		
Srinivasan; Subhashini	Kirkland	WA		
Gibson; Marylou G.	Carlsbad	CA		
Morris; Arvia E.	Seattle	WA		
McGrew; Jeffrey T.	Seattle	WA		

US-CL-CURRENT: 514/8; 514/12, 514/2, 514/885, 530/350, 536/23.1, 536/23.4, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 13. Document ID: US 5961974 A

L2: Entry 13 of 13 File: USPT Oct 5, 1999

US-PAT-NO: 5961974
DOCUMENT-IDENTIFIER: US 5961974 A

TITLE: Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same

DATE-ISSUED: October 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
Fanslow; William C.	Federal Way	WA		
Spriggs; Melanie K.	Seattle	WA		

US-CL-CURRENT: 424/154.1; 424/130.1, 424/141.1, 424/143.1, 424/144.1, 424/153.1, 424/173.1, 435/326, 435/332, 435/334, 435/343, 435/343.1, 435/343.2, 435/346, 435/452, 435/70.21, 530/387.1, 530/387.9, 530/388.1, 530/388.22, 530/388.7, 530/388.73, 530/388.75

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

Generate Collection | Print

Term	Documents
CD40L.USPT,PGPB.	755
CD40LS.USPT,PGPB.	2
CD40.USPT,PGPB.	1969
CD40S	0
LIGAND.USPT,PGPB.	54478
LIGANDS.USPT,PGPB.	44605
(1 AND (CD40L OR (CD40 ADJ LIGAND))).USPT,PGPB.	13
(L1 AND (CD40L OR CD40 ADJ LIGAND)).USPT,PGPB.	13

Display Format: - Change Format

Previous Page Next Page

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
CD30L.USPT.	55
CD30LS	0
(CD30L AND 6).USPT.	15
(L6 AND CD30L).USPT.	15

Database:
- US Patents Full-Text Database
- US Pre-Grant Publication Full-Text Database
- JPO Abstracts Database
- EPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

Search: L8

Refine Search

Recall Text | Clear

Search History

DATE: Friday, May 02, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=ADJ			
L8	L6 and cd30L	15	L8
DB=USPT,PGPB; PLUR=YES; OP=ADJ			
L7	L6 and cd30L	39	L7
L6	L5 same (treat$ or therap$ or prevent$ or block$ or suppress$ or inhibit$)	248	L6
L5	(cd40L or cd40 adj ligand or gp39) same (cancer$ or tumor$ or tumour$)	543	L5
L4	L3 and photodynamic	1	L4
L3	L2 and (cancer$ or tumor$ or tumour$)	13	L3
L2	L1 and (cd40L or cd40 adj ligand)	13	L2
L1	fanslow-william$	22	L1

END OF SEARCH HISTORY

WEST

End of Result Set

☐ Generate Collection Print

L9: Entry 6 of 6 File: USPT Jun 29, 1999

DOCUMENT-IDENTIFIER: US 5916910 A
TITLE: Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore

Brief Summary Text (86):
antiarthritic agents, such as anti-CD4 monoclonal antibodies, phospholipase A1 inhibitor, loteprednol, tobramycin, combinations of loteprednol and tobramycin, salnacedin, amiprilose, anakinra, anergix, anti-B7 antibody, anti-CD3H, anti-gp39, anti-MHC MAbs, antirheumatic peptides, anti-Tac(Fv)-PE40, AP-1 inhibitors, AR-324, purine nucleotide phosphorylase inhibitors (e.g., BCX-5), bindarit, CD2 antagonist (e.g., BTI-322), campath-1H, CD4 antagonist (e.g., CE9.1 and SB-210396), tumor necrosis factor antagonist (e.g., p80 TNFR, rhTNFbp, peptide T, CenTNF, thalidomide, CDP-571 and TBP-1), cobra venom factor, interleukin 1a agonist (e.g., cytogenin), interleukin 2 receptor antagonist (e.g., dacliximab), ICAM 1 antagonist (e.g., enlimomab), interleukin 1 beta converting enzyme inhibitors (e.g., ICE-inhibitors), interferons (e.g., thymocartin), interleukin-10, interleukin-13, interleukin 1 antagonist (e.g., SR-31747 and TJ-114), interleukin-2 antagonist (e.g., sirolimus), phospholipase C inhibitor, neurokinin 1 antagonist (e.g., L-733060), laflunimus, leflunomide, leucotriene antagonists, levamisole, LFA3TIP, macrocyclic lactone, MHC class II inhibitors, mizoribine, mycophenolate mofetil, NfkB inhibitors, oncolysin CD6, peldesine, pidotimod, PKC-RACK inhibitors, PNP inhibitors, reumacon, CD28 antagonist, roquinimex, RWJ-50271, subreum, T7 vector, tacrolimus, VLA antagonist (e.g., TBC-772), transforming growth factor beta agonist, methionine synthase inhibitors (e.g., vitamin B12 antagonist), adenosine A2 receptor agonist (e.g., YT-146), CD5 antagonist (e.g., zolimomab), 5-lipoxygenase inhibitor (e.g., zileuton, tenidap, and ABT-761), cyclooxygenase inhibitor (e.g., tenoxicam, talmetacin, piroxicam, piroxicam cinnamate, oxaprozin, NXTHIO, ML-3000, mofezolac, nabumetone, flurbiprofen, aceclofenac, diclofenac, and dexibuprofen), metalloproteinase inhibitor (e.g., XR-168, TNF convertase inhibitors, GI-155704A, AG-3340 and BB-2983), nitric oxide synthase inhbitors (i.e, ARL-16556), phospholipase A2 inhibitor (e.g., ARL-67974), selectin antagonist (e.g., CAM inhibitors), leucotriene B4 antagonist (e.g., CGS-25019C), collagenase inhibitor (e.g., GR-129574A), cyclooxygenase 2 inhibitor (e.g., meloxicam), thromboxane synthase inhibitor (e.g., curcumin), cysteine protease inhibitor (e.g., GR-373), metalloproteinase inhibitor (D-5410), lipocortins synthesis agonist (e.g., rimexolone, predonisolone 21-farnesylate, HYC-141, and deflazacort), chelating agent (diacerein), elastase inhibitors, DNA directed RNA polymerase inhibitor (e.g., estrogens), oxygen radical formation antagonist (e.g., glucosamine sulfate), thrombin inhibitors (e.g., GS-522), collagen inhibitors (e.g., halofuginone), hyaluronic acid agonist (e.g., NRD-101, hylan, Dispasan, and Hyalart), nitric oxide antagonists (e.g., hydroxocobalamin), stromelysin inhibitors (e.g., L-758354), prostaglandin E1 agonist (e.g., misoprostol, and misoprostol+diclofenac), dihydrofolate reductase inhibitor (e.g., trimetrexate, and MX-68), opioid antagonist (e.g., nalmefene), corticotropin releasing factor antagonist (e.g., NBI-103, and NBI-104), proteolytic enzyme inhibitor (e.g., protease nexin-1, and NCY-2010), bradykinin antagonist (e.g., tachykinin antagonists, and NPC-17731), growth hormone antagonist (e.g., octreotide), phosphodiesterase IV inhibitor (e.g., PDEIV inhibitors), gelatinase inhibitor (e.g., REGA-3G12), free radical scavengers (e.g., SIDR-1026), prostaglandin synthase inhibitors (e.g., sulfasalazine), phenylbutazone, penicillamine, salsalate, azathioprine, indomethacin, meclofenamate sodium, gold sodium thiomalate, ketoprofen, auranofin, aurothioglucose, tolmetin sodium, and the

like;

Brief Summary Text (111):
multiple sclerosis agents, such as 4-aminopyridine, 15.+-.deoxyspergualin, ACTH, amantadine, antibody adjuvants (e.g., poly-ICLC, and poly-IC+poly-L-lysine+carboxymethylcellulose), anti-cytokine MAb (CDP-835), anti-inflammatory (e.g., CY-1787, and CY-1503), anti-selectin MAb (e.g., CY-1787), anti-TCR MAb (e.g., NBI-114, NBI-115, and NBI-116), bacloten, bethanechol chloride, carbamazepine, carbohydrate drugs (e.g., CY-1503), clonazepam, CNS and immune system function modulators (e.g., NBI-106, and NBI-107), cyclophosphamide, cyclosporine A, cytokines (e.g., IFN-.alpha., alfaferone, IFN-.beta. 1b, betaseron, TGF-.beta.2, PEG-TGF-.beta.2, betakine, IFN-.beta./Rebif, frone, interferon-.beta., and IFN-.beta.), CD4+T cell inhibitors (e.g., AnergiX), CD28 antagonists (e.g., B7-1, B7-2, and CD28), directcytotoxicity therapies (e.g., benzoporphyrin derivative (BPD)), FK-506, growth factors (e.g., glial growth factor, GGF, nerve growth factors, TGF-.beta.2, PEG-TGF-.beta.2, and betakine), humanized MAb (e.g., anti-IFN-.gamma.MAb, smart anti-IFN-.gamma.MAb, anti-Tac antibody, and smart anti-Tac antibody), humanized anti-CD4 MAb (e.g., anti-CD4 MAb, centara), hydrolase stimulants (e.g., castanospermine), IFN-.alpha., IFN-.gamma. antagonist (e.g., anti-IFN-.gamma. MAb, and smart anti-IFN-.gamma. MAb), IL-2 antagonists (e.g., tacrolimus, FK-506, FR-900506, Fujimycin, Prograf, IL-2 fusion toxin, and DAB.sub.389 IL-2), IL-4 antagonists (e.g., IL-4 fusion toxin, and DAB.sub.389 IL-4), immune-mediated neuronal damage inhibitors (e.g., NBI-114, NBI-115, and NBI-116), immunoglobins, immunostimulants (e.g., poly-ICLC, edelfosine, ALP, ET-18-OCH3, ET-18-OME, NSC-24, and poly-IC+poly-L-lysine+carboxymethylcellulose), immunosuppressants (e.g., azathioprine, AI-100 animal protein, rDNA human protein AI-101, peptide, AI-102, castanospermine, tacrolimus, FK-506, FR-900506, Fujimycin, Prograf, anti-leukointegrin MAb, Hu23F2G, primatized anti-CD4 antibody, CE9.1, Galaptin 14-1, GL14-1, Lectin-1, recombinant IML-1, linomide, roquinimex, LS-2616, transcyclo-pentanyl purine analogs, MS-6044, spanidin, 15-deoxyspergualin, deoxyspurgiline, gusperimus HCL, NSC-356894, NKT-01, TCR, CD3/Ti, cyclosporine, OL-27-400, SandImmune, Human IL-10, monogens, anti-TCR MAbs, TCAR MAbs, Monogen TM19, Monogen TM27, Monogen TM29, Monogen TM31, peptigen TP12, anti-CD4 MAb, cantara, immunophilins, VX-10367, VX-10393, VX-10428, synthetic basic copolymer of amino acids, copolymer-1, COP-1, T lymphocyte immunofusion (TIF) protein, and cyclophosphamide), integrin antagonists (e.g., anti-integrin (cell adhesion molecule .alpha.4.beta.1 integrin) MAbs, AN-100225, and AN-100226), interferon agonists (e.g., poly-ICLC, and poly-IC+poly-L-lysine+carboxymethylcellulose), interferon-.beta.-1b, isoprinosine, IV methylprednisolone, macrolides (e.g., tacrolimus, FK-506, FR-900506, Fujimycin, and Prograf), MAO B inhibitors (e.g., selegiline, and Parkinyl), methotrexate, mitoxantrone, muscle relaxants (e.g., RGH-5002), muscarinic antagonists (e.g., RGH-5002), neurosteroids (e.g., NBI-106, and NBI-107), octapeptides (e.g., peptide T), oxybutinin chloride, oxygen free radical antagonists (e.g., tetrandrine, biobenzylisoquinoline alkaloid), peptide agonists (e.g., peptide T), phenoxybenzamine, phospholipase C inhibitors (e.g., edelfosine, ALP, ET-18-OCH3, ET-18-OME, NSC-24), photodynamic therapies (e.g., benzoporphyrin derivative (BPD)), plasmapheresis, platelet activating factor antagonists (e.g., ginkgolide B, and BN-52021), potassium channel antagonists (e.g., aminodiaquine, and EL-970), propranolol, prostaglandin synthase inhibitors (e.g., sulfasalazine, salazosulfa-pyridine, PJ-306, SI-88, azulfidine, salazopyrin), protease antagonists (e.g., ginkgolide B, and BN-52021), recombinant soluble IL-1 receptors, spergualin analogs (e.g., spanidin, 15-deoxyspergualin, deoxyspurgiline, gusperimus HCl, NSC-356894, NKT-01), TCR peptide decoys (e.g., NBI-114, NBI-115, and NBI-116), TCR peptidomimetic decoys (e.g., NBI-114, NBI-115, and NBI-116), TCR peptide vaccines (e.g., AI-208 (V.beta.6.2/6.5 phenotype)), selectin antagonists (e.g., lectin-1, and recombinant IML-1), soluble TNF receptor I, TCARs (e.g., TCR, CD3/Ti, and peptigen TP12), TNF antagonists (e.g., thalidomide, and TNF inhibitors), tricyclic antidepressants, and the like;

Brief Summary Text (116):
psoriasis agents, such as 5-LO inhibitors (e.g., Wy-50295, Wy-49232, Lonapalene, RS-43179, MK-886, L-663536, ETH-615, DUP-654, Zileuton, epocarbazolin-A, and A-64077), 5-LO/CO inhibitors (e.g., BF-397, Tenidap, CP-309, and CP-66248), angiogenesis inhibitors (e.g., platelet factor 4), anticancer antibiotic (e.g., AGM-1470, and TNP-470), anti-inflammatory cytochrome P450 oxidoreductase inhibitors

(e.g., DuP-630, and DuP-983), antiproliferative compounds (e.g., Zyn-Linker), arachidonic acid analogues (e.g., CD581, and CD554), arachidonic acid antagonists (e.g., Lonopalene, RS-43179, triamcinolone acetonide with penetration enhancer Azone, betamethasone dipropionate steroid wipe, G-202, Halobetasol propionate, ultravate, Halometasone, C-48401-Ba, and Sicorten), beta-glucan receptor antagonists, betamethasone steroid wipes, calcium metabolic moderators (e.g., Tacalcitol, Bonealfa, TV-02 ointment, Ro-23-6474, KH-1060, Calcipotriol, BMS-181161, BMY-30434, Dovonex, and Divonex), CD4 binding inhibitors (e.g., PIC 060), cell adhesion compounds (e.g., CY-726, VCAM-1, ELAM-1, and ICAM), cell adhesion inhibitors (e.g., selectin inhibitor, GM-1930), cellular aging inhibitors (e.g., Factor X), corticosteroids (e.g., Halobetasol propionate, ultravate, Halometasone, C-48401-Ba, and Sicorten), cyclosporin analogues (e.g., IMM-125), dihydrofolate reductase inhibitors (e.g., G-301, dichlorobenzoprim, methotrexate, and methotrexate in microsponge delivery system), E-selectin inhibitors (e.g., ISIS 4730), endogenous active form of vitamin D.sub.3 (e.g., Calcitriol, and Du-026325), fibroblast growth factor antagonists (e.g., Saporin mitotoxin, and Steno-Stat), fumagillin analogues (e.g., AGM-1470, and TNP-470), G-proteins and signal transduction compounds (e.g., CPC-A), gel formulations for acne (e.g., nicotinamide, N-547, and Papulex), growth hormone antagonists (e.g., Octreotide, Sandostatin, Lanreotide, angiopeptin, BIM-23014, and Somatuline), humanized antibodies (e.g., anti-CD4 antibody), hydroorotate dehydrogenase inhibitors (e.g., Brequinar sodium, bipenquinate, and DuP-785), ICAM-1 inhibitors (e.g., ISIS 939), IL-1 and other cytokine inhibitors (e.g., Septanil), IL-1 converting ezyme inhibitors, IL-1 receptor antagonists (e.g., Antril), IL-2 antagonists (e.g., Tacrolimus, Prograf, and FK-506), IL-2 receptor-targeted fusion toxins (DAB389IL-2), IL-8 receptors, immunostimulants (e.g., Thymopentin, and Timunox), immunosuppressants (e.g., XomaZyme-CD5 Plus, cyclosporine, Sandimmune, SR-31747, anti-CD11, 18 MAb, Tacrolimus, Prograf, FK-506, and FK-507), immunosuppressive agents targeting FK506 (e.g., immunophilins, VX-10367, and VX-10428), immunotoxins MAb directed against CD antigen (e.g., XomaZyme-CD5 Plus), leukotriene antagonists (e.g., Sch-40120, Wy-50295, and Wy-49232), leukotriene B4 antagonists (e.g., SC-41930, SC-50605, SC-48928, ONO-4057, LB-457, LY-255283, LY-177455, LY-223982, LY-223980, and LY-255253), leukotriene synthesis inhibitors (MK-886, and L-663536), lipase clearing factor inhibitors (e.g., 1-docosanol, and lidakol), lipid encapsulated reducing agent (e.g., Dithranol), liposomal gel (e.g., Dithranol), LO inhibitors (e.g., CD581, CD554, Masoprocol, and Actinex), lithium succinate ointments (e.g., lithium salts, and Efalith), LO/CO inhibitors (e.g., P-8892, P-8977, CHX-108, and FPL-62064), membrane integrity agonists (e.g., lithium salts, and Efalith), microtubule inhibitors (e.g., Posophyliotoxin-containing compound, and Psorex), octapeptide somatostatin analogues (e.g., Lanreotide, angiopeptin, BIM-23014, and Somatuline), oligonucleotides (e.g., ISIS 4730, ISIS 3801, ISIS 1939, and IL-1 inhibitors), peptide agonists (e.g., octapeptide, and peptide T), PKC inhibitors, phospholipase A2 compounds, pospholipase D compounds, photodynamic anticancer agents (e.g., 5-aminolevulinic acid, and 5-ALA), photodynamic therapies (e.g., benzoporphyrin derivative, synthetic chlorins, synthetic porphyrins, and EF-9), photosensitizer (e.g., Porfirmer sodium), PKC inhibitors (e.g., Safingol, and Kynac), platelet activating factor antagonists (e.g., TCV-309), platelet aggregation inhibitors (e.g., CPC-A), prodrug NSAIDs (e.g., G-201), prostaglandin agonist (e.g., eicosapentaenoic acid+gamma-linolenic acid combination, and Efamol Marine), protein inhibitors (e.g., SPC-103600, and SPC-101210), protein kinase C (PKC) inhibitors (e.g., Ro-31-7549, Ro-31-8161, and Ro-31-8220), protein synthesis antagonists (e.g., Calcitriol, Du-026325, LG-1069, LG-1064, AGN-190168, Namirotene, and CBS-211A), purine nucleoside phosphorylase inhibitors (e.g., BCX-34), radical formation agonists (e.g., benzoporphyrin derivative), recombinant antileukoproteinases (e.g., ALP-242), retinoids (e.g., BMY-30123, LG-1069, and LG-1064), retinoid derivatives (e.g., AGN-190168), rapamycin binding proteins (FKBP) (e.g., immunophilins, VX-10367, and VX-10428), second generation monoaromatic retinoids (e.g., Acitretin, and Neotigason), soluble IL-1, IL-4 and IL-7 receptors, somatostatin and somatostatin analogues (e.g., Octreotide, and Sandostatin), steroids, (e.g., AGN-191743), streptomyces anulatus isolates (e.g., epocarbazolin-A), superoxide dismutase (e.g., EC-SOD-B), thymidylate synthase inhibitors (e.g., AG-85, MPI-5002, 5-FU in biodegradable gel-like matrix, 5-FU and epinephrine in biodegradable gel-like matrix, and AccuSite), topical formulations (e.g., P-0751, and P-0802), transglutaminase inhibitors, tyrphostin EGF receptor kinase blockers (e.g., AG-18, and AG-555), VCAM-1 inhibitors (e.g., ISIS 3801), vitamin D analogues (e.g., Ro-23-6474, KH-1060, Calcipotriol, BMS-181161, BMY-30434,

Dovonex, and Divonex), vitamin D.sub.3 analogues (e.g., Tacalcitol, Bonealfa, TV-02 ointment), and vitamin D.sub.3 derivatives (e.g., 1,2-diOH-vitamin D.sub.3), and the like;

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
CD40L.USPT.	248
CD40LS.USPT.	2
CD40.USPT.	889
CD40S	0
LIGAND.USPT.	40761
LIGANDS.USPT.	33419
GP39.USPT.	121
GP39S	0
CD30L.USPT.	55
CD30LS	0
PHOTODYNAMIC$	0
((CD40L OR CD40 ADJ LIGAND OR GP39 OR CD30L) AND PHOTODYNAMIC$).USPT.	6

There are more results than shown above. Click here to view the entire set.

Database:
US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L9

Refine Search

Recall Text | Clear

Search History

DATE: Friday, May 02, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=ADJ			
L9	(cd40L or cd40 adj ligand or gp39 or cd30L) and photodynamic$	6	L9
L8	L6 and cd30L	15	L8
DB=USPT,PGPB; PLUR=YES; OP=ADJ			
L7	L6 and cd30L	39	L7
L6	L5 same (treat$ or therap$ or prevent$ or block$ or suppress$ or inhibit$)	248	L6
L5	(cd40L or cd40 adj ligand or gp39) same (cancer$ or tumor$ or tumour$)	543	L5
L4	L3 and photodynamic	1	L4
L3	L2 and (cancer$ or tumor$ or tumour$)	13	L3
L2	L1 and (cd40L or cd40 adj ligand)	13	L2
L1	fanslow-william$	22	L1

END OF SEARCH HISTORY

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
CD30L.DWPI,EPAB,JPAB,USPT,PGPB.	278
CD30LS	0
TUMOR$	0
TUMOR.DWPI,EPAB,JPAB,USPT,PGPB.	36175
TUMORA.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORACTIVITY.DWPI,EPAB,JPAB,USPT,PGPB.	9
TUMORADENOCA.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORAGENT.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORAL.DWPI,EPAB,JPAB,USPT,PGPB.	661
TUMORALE.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORALLY.DWPI,EPAB,JPAB,USPT,PGPB.	45
((CD30L)SAME(TUMOR$ OR TUMOUR$ OR CANCER$)SAME (TREAT$ OR INHIBIT$ OR BLOCK$ OR SUPPRESS$ OR PREVENT$ OR THERAP$)).USPT,PGPB,JPAB,EPAB,DWPI.	11

There are more results than shown above. Click here to view the entire set.

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L12

Refine Search

Recall Text | Clear

Search History

DATE: Friday, May 02, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L12	(cd30L)same(tumor$ or tumour$ or cancer$)same (treat$ or inhibit$ or block$ or suppress$ or prevent$ or therap$)	11	L12
DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L11	(cd40L or cd40 adj ligand or gp39 or cd30L) and photodynamic$	1	L11
L10	L9	0	L10
DB=USPT; PLUR=YES; OP=ADJ			
L9	(cd40L or cd40 adj ligand or gp39 or cd30L) and photodynamic$	6	L9
L8	L6 and cd30L	15	L8
DB=USPT,PGPB; PLUR=YES; OP=ADJ			
L7	L6 and cd30L	39	L7
L6	L5 same (treat$ or therap$ or prevent$ or block$ or suppress$ or inhibit$)	248	L6
L5	(cd40L or cd40 adj ligand or gp39) same (cancer$ or tumor$ or tumour$)	543	L5
L4	L3 and photodynamic	1	L4
L3	L2 and (cancer$ or tumor$ or tumour$)	13	L3
L2	L1 and (cd40L or cd40 adj ligand)	13	L2
L1	fanslow-william$	22	L1

END OF SEARCH HISTORY

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
CD30L.DWPI,EPAB,JPAB,USPT,PGPB.	278
CD30LS	0
TUMOR$	0
TUMOR.DWPI,EPAB,JPAB,USPT,PGPB.	36175
TUMORA.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORACTIVITY.DWPI,EPAB,JPAB,USPT,PGPB.	9
TUMORADENOCA.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORAGENT.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORAL.DWPI,EPAB,JPAB,USPT,PGPB.	661
TUMORALE.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORALLY.DWPI,EPAB,JPAB,USPT,PGPB.	45
((CD30L)SAME(TUMOR$ OR TUMOUR$ OR CANCER$)SAME (TREAT$ OR INHIBIT$ OR BLOCK$ OR SUPPRESS$ OR PREVENT$ OR THERAP$)).USPT,PGPB,JPAB,EPAB,DWPI.	11

There are more results than shown above. Click here to view the entire set.

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L12

Refine Search

Recall Text | Clear

Search History

DATE: Friday, May 02, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L12	(cd30L)same(tumor$ or tumour$ or cancer$)same (treat$ or inhibit$ or block$ or suppress$ or prevent$ or therap$)	11	L12
DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L11	(cd40L or cd40 adj ligand or gp39 or cd30L) and photodynamic$	1	L11
L10	L9	0	L10
DB=USPT; PLUR=YES; OP=ADJ			
L9	(cd40L or cd40 adj ligand or gp39 or cd30L) and photodynamic$	6	L9
L8	L6 and cd30L	15	L8
DB=USPT,PGPB; PLUR=YES; OP=ADJ			
L7	L6 and cd30L	39	L7
L6	L5 same (treat$ or therap$ or prevent$ or block$ or suppress$ or inhibit$)	248	L6
L5	(cd40L or cd40 adj ligand or gp39) same (cancer$ or tumor$ or tumour$)	543	L5
L4	L3 and photodynamic	1	L4
L3	L2 and (cancer$ or tumor$ or tumour$)	13	L3
L2	L1 and (cd40L or cd40 adj ligand)	13	L2
L1	fanslow-william$	22	L1

END OF SEARCH HISTORY